To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
β-lactamase-mediated resistance in MDR-Pseudomonas aeruginosa from Qatar
Örebro University, School of Science and Technology. Department of Laboratory Medicine and Pathology, Microbiology Division, Hamad Medical Corporation, Doha, Qatar. (The Life Science Centre-Biology)ORCID iD: 0000-0002-6186-7770
Örebro University, School of Science and Technology. (The Life Science Centre-Biology)
Department of Microbiology and Immunology, Weill Cornell Medicine-Qatar, Doha, Qatar.
Örebro University, School of Medical Sciences.ORCID iD: 0000-0001-5939-2932
Show others and affiliations
(English)Manuscript (preprint) (Other academic)
National Category
Other Biological Topics
Identifiers
URN: urn:nbn:se:oru:diva-87552OAI: oai:DiVA.org:oru-87552DiVA, id: diva2:1503372
Available from: 2020-11-24 Created: 2020-11-24 Last updated: 2020-11-24Bibliographically approved
In thesis
1. Molecular Epidemiology and Mechanisms of Antibiotic Resistance in Clinical Isolates of Pseudomonas aeruginosa from Qatar
Open this publication in new window or tab >>Molecular Epidemiology and Mechanisms of Antibiotic Resistance in Clinical Isolates of Pseudomonas aeruginosa from Qatar
2020 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Inappropriate and excessive use of antibiotics promotes antimicrobial resistance (AMR), particularly in Gram-negative bacteria (GNB). There is a noticeable increase in nosocomial infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa, which is associated with significant morbidity, mortality, and an increase in cost management. Although this is a global problem, there is a lack of sufficient data on regional differences that can contribute towards effective AMR management. This thesis presents a study of MDR-P. aeruginosa at five different hospitals in Qatar conducted prospectively between October 2014 - September 2017. The aim was to study the epidemiology, microbiological and clinical characteristics of MDR-P. aeruginosa infections as well as investigate the activity of new antibiotic combinations against these bacteria. The prevalence of MDR-P. aeruginosa isolates in the first year was 8.1% (205/2533), isolated from different clinical specimens, but the majority were from respiratory infections (44.9%, n=92). Most cases were exposed to antibiotics during the 90 days prior to isolation (85.4%, n=177), and the resistance to cefepime, ciprofloxacin, piperacillin/tazobactam, meropenem was >90%. To compare pre- and post-Antimicrobial Stewardship Program, there was a significant reduction in antibiotic consumption by 30.4% of total inpatient antibiotic prescriptions (p=0.008) and the prevalence of MDR-P. aeruginosa significantly declined from 9% to 5.4% (p=0.019). The in vitro investigation of ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T) against MDR-P. aeruginosa isolates, showed promising results with susceptibility of 68.8% (n=141/205) and 62.9% (n=129/205), respectively, which was higher than other antipseudomonal agents except colistin. Seventy-five isolates that were sequenced belonged to 29 different sequence types, with ST235 being predominant at 21.3% (16/75). Among the 42 isolates that were resistant to CZA and/or C/T, the most prevalent genes were blaOXA-488 and blaVEB-9 detected in 45.2% (19/42) of isolates. Spearman’s analysis showed that resistance to CZA and C/T were positively correlated with the presence of blaOXA-10, blaPDC-2a, blaVIM-2, and blaVEB-9 , respectively. The study highlights potential key mechanisms that could explain the resistance of MDR-P. aeruginosa to the new antibiotic combinations.

Place, publisher, year, edition, pages
Örebro: Örebro University, 2020. p. 92
Series
Örebro Studies in Life Science, ISSN 1653-3100 ; 17
Keywords
Antibiotics, C/T, CZA, MDR, Pseudomonas aeruginosa, ST235, VEB, VIM
National Category
Other Biological Topics
Identifiers
urn:nbn:se:oru:diva-85159 (URN)978-91-7529-353-0 (ISBN)
Public defence
2020-12-16, Örebro universitet, Långhuset, Hörsal L2, Fakultetsgatan 1, Örebro, 13:15 (English)
Opponent
Supervisors
Note

I den fysiska versionen av avhandlingen är den angivna tidpunkten för avhandlingen 21 oktober, 2020, 13:00 med plats Hörsal F, Forumhuset, Örebro universitet. Disputationen blev dock inställd och fick nytt datum och plats (dessa anges ovan).

Available from: 2020-08-26 Created: 2020-08-26 Last updated: 2023-01-26Bibliographically approved

Open Access in DiVA

No full text in DiVA

Authority records

Sid Ahmed, MazenKhan, Faisal AhmadSöderquist, BoJass, Jana

Search in DiVA

By author/editor
Sid Ahmed, MazenKhan, Faisal AhmadSöderquist, BoJass, Jana
By organisation
School of Science and TechnologySchool of Medical Sciences
Other Biological Topics

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 137 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf